ストックスクリーナーアプリを入手
0.00
100.00%
-54.65
アフターアワーズ：
54.70
54.70
+
前日終値:
$54.65
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$4.50B
収益：
-
当期純損益:
$-269.44M
株価収益率:
0.00
EPS:
-3.75
ネットキャッシュフロー:
$-262.63M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$57.35
Akero Therapeutics Inc Stock (AKRO) Company Profile
名前
Akero Therapeutics Inc
セクター
電話
650-487-6488
住所
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
0.00 | 4.50B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-04 | 開始されました | TD Cowen | Buy |
| 2025-01-30 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-01-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-18 | 開始されました | Citigroup | Buy |
| 2024-04-22 | 再開されました | BofA Securities | Neutral |
| 2023-09-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 開始されました | UBS | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | 開始されました | Guggenheim | Buy |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2020-07-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-02 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Evercore ISI | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
| 2019-07-15 | 開始されました | Jefferies | Buy |
| 2019-07-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Akero Therapeutics Inc (AKRO) 最新ニュース
Signal Recap: How does Akero Therapeutics Inc score in quality rankings2026 Biggest Moves & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-11 23:57:58 - baoquankhu1.vn
Panic Selling: What is Akero Therapeutics Incs revenue forecastWeekly Market Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Treasury Yields: Is Akero Therapeutics Inc stock good for income investorsEarnings Recap Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (AKRO) - Stock Traders Daily
What’s Driving The Super Rally In Akero Shares On Thursday Morning? - Stocktwits
Published on: 2026-03-01 05:11:32 - baoquankhu1.vn
Aug Chart Watch: Can Akero Therapeutics Inc maintain sales growthDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Short Covering: Does Akero Therapeutics Inc meet Warren Buffetts criteriaPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Macro Review: Is Akero Therapeutics Inc stock influenced by commodity pricesGap Down & AI Forecasted Entry/Exit Points - baoquankhu1.vn
AKRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Akero Therapeutics Inc. stock a falling knife or bargain buyRecession Risk & AI Powered Market Trend Analysis - mfd.ru
Resistance Check: Can Akero Therapeutics Inc stock outperform in a bear marketJuly 2025 Selloffs & Precise Buy Zone Identification - baoquankhu1.vn
Merger Talk: Is Akero Therapeutics Inc backed by strong institutional buying2025 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Is Akero Therapeutics Inc. backed by strong institutional buyingJuly 2025 Fed Impact & Stock Market Timing Techniques - mfd.ru
Akero Therapeutics (NASDAQ: AKRO) holder Janus Henderson now at 4.1% - Stock Titan
Weekly Earnings: Does Akero Therapeutics Inc have consistent dividend growthMarket Risk Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Growth Value: Can Solid Biosciences Inc withstand a market correctionMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn
RTW Investments exits Akero Therapeutics (AKRO), reporting 0.0% ownership - Stock Titan
Can Akero Therapeutics Inc. maintain its current growth rateJuly 2025 PreEarnings & High Yield Equity Trading Tips - mfd.ru
Pullback Watch: Should you avoid Akero Therapeutics Inc stock right now2025 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
What’s Akero Therapeutics Inc.’s historical returnPortfolio Performance Report & Daily Risk Controlled Trade Plans - mfd.ru
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Aug Wrap: Is Akero Therapeutics Inc. stock showing strong momentumPrice Action & Safe Entry Point Alerts - mfd.ru
Can Akero Therapeutics Inc. maintain sales growthCPI Data & Daily Entry Point Trade Alerts - mfd.ru
Analyst Downgrade: Is Akero Therapeutics Inc stock good for income investors2025 Investor Takeaways & High Yield Stock Recommendations - baoquankhu1.vn
TD Cowen Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN
Is Akero Therapeutics Inc. stock affected by interest rate hikesJuly 2025 WrapUp & AI Powered Market Entry Strategies - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating Growth in Biotechnology with a 3.39% Potential Upside - DirectorsTalk Interviews
Behavioral Patterns of AKRO and Institutional Flows - Stock Traders Daily
Analyst Calls: Is Akero Therapeutics Inc stock showing strong momentumPortfolio Growth Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Movers: Is Akero Therapeutics Inc. stock influenced by commodity prices2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Does Akero Therapeutics Inc. have consistent dividend growth2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Investment Report: Will Akero Therapeutics Inc outperform the market in YEARJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Income Plays: Is INTU a stock for growth or value investorsJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Guidance Update: What is the earnings history of Akero Therapeutics Inc2025 Volume Leaders & Safe Capital Growth Tips - baoquankhu1.vn
(AKRO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Quarterly Trades: How does ProShares Trust ProShares UltraPro Short QQQ perform in inflationary periodsJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
In Vivo’s Deals Of The Year: Cast Your Vote! - Citeline News & Insights
RSI Check: Does Akero Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring Growth Potential Amid a 3.39% Upside - DirectorsTalk Interviews
Sentiment Recap: Does Akero Therapeutics Inc meet Warren Buffetts criteriaWeekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn
Akero Therapeutics shareholders approve Novo Nordisk merger - MSN
December blockbusters push biopharma deal value to record high - BioWorld MedTech
Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025 - Citeline News & Insights
Aug Technicals: Is CKX Lands Inc a potential multi baggerMarket Activity Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn
Inflation Data: Is ISPC still a buy after recent gainsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-01-14 06:28:29 - Bộ Nội Vụ
Insider Buy: What is Akero Therapeutics Incs revenue forecastJuly 2025 Earnings & Safe Capital Investment Plans - baoquankhu1.vn
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating the Biotech’s 3.39% Potential Upside - DirectorsTalk Interviews
Akero Therapeutics Inc (AKRO) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
大文字化:
|
ボリューム (24 時間):